Biophage signs a MOU with two US Companies for developing new generation of PDS® biosensors
Biophage Pharma Inc. announced that it has signed a memorandum of understanding with two U.S. companies, Indus Instruments, and International Science Consulting, LLC (ISC), for the development and manufacturing of the a new generation of PDS® biosensors.
Under this MOU, Indus and ISC will develop for Biophage proprietary equipment for the detection of live bacterial pathogens and their toxins. As compensation, Indus and ISC will receive US$50,000 and 3,800,000 non-transferable warrants, each such warrant entitling the holder thereof to purchase one common share of the capital of Biophage at any time, for a period of two years after the date of its grant. Out of the 3,800,000 abovementioned warrants, 2,800,000 will be exercisable at a price of CAN$0.12 and 1,000,000 will be exercisable at a price of CAN$0.30. The parties have agreed to enter into a more detailed development agreement.
Other news from the department business & finance
These products might interest you
Octet R2 / Octet R4 / Octet R8 by Sartorius
Full power on 2, 4 or 8 channels: Label-free and GxP-compliant analysis of molecular interactions
Innovative label-free real-time protein quantification, binding kinetics and rapid screenings
Octet RH16 and RH96 by Sartorius
Efficient protein analysis for process optimisation and manufacturing control in high-throughput
Label-free protein quantification and characterization of protein-protein interactions
Octet SF3 by Sartorius
Surface Plasmon Resonance (SPR) using Single Dynamic Injections for Kinetics and Affinities
Curvature is Key - Adding a ‘Third Dimension’ to the Binding Curve
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
